Additional data, including paired genomics and immunotherapy treatment outcomes, will be needed to validate these conclusions; nevertheless, our analysis strongly suggests loss of function JAK1 alterations represents a tumor-intrinsic mechanism of immune evasion and possibly renders MSI-H tumors resistant to checkpoint inhibitors. This evidence concerns the gene JAK1 and neoplasm.